|
Match
|
Document |
Document Title |
|
|
7608601 |
4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
The present invention relates to the use of nucleoside derivatives of formula I
wherein B signifies a 9-purinyl residue B1 of formula
or a 1-pyrimidyl residue B2 of formula...
|
|
|
7589075 |
Use of an adenosine A3 receptor agonist for inhibition of viral replication
The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In...
|
|
|
7572800 |
Combination therapy to treat hepatitis B virus
The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B...
|
|
|
7569574 |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
The invention relates to new purine derivatives of general formula
wherein R 1 to R 4 are defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and...
|
|
|
7498334 |
Pyrrolopyrimidines as phosphodiesterase VII inhibitors
Pyrrolopyrimidine derivatives of the formula I
in which R 3 , R 4 , R 5 , R 6 and X are as defined in claim 1 , act as phosphodiesterase VII inhibitors and can be employed for the treatment...
|
|
|
7495004 |
Purine derivatives as liver X receptor agonists
The invention relates to methods for the treatment or prevention of an LXR mediated disease or condition, including cardiovascular disease and atherosclerosis, novel compounds of formula (I) for...
|
|
|
7256196 |
Purine cytokine inhibitors
The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian...
|
|
|
7253154 |
Substituted thiazolopyrimidines as xanthine oxidase inhibitors
The invention relates to compounds of the following formula (I) or their salts:
in which R 1 represents OR 4 or others, in which R 4 is an alkyl group having 1-8 carbon atoms which may have...
|
|
|
7253175 |
Method for treating athlete's foot
A method of treating a patient having a fungal infection comprises administering an effective fungal infection treatment amount of an antiviral agent, such as valacyclovir, to eliminate the...
|
|
|
7115614 |
Method of treating brain ischemia
The present invention relates to a method of treating brain ischemia in which a xanthine derivative represented by formula (I):
or a pharmaceutically acceptable salt thereof, as an active...
|
|
|
RE39112 |
Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes
The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action. A purine...
|
|
|
7005430 |
Fused purine derivatives
A condensed purine derivative represented by Formula (I):
wherein X—Y-Z represents R 1 N—C═O or N═C—W, R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl...
|
|
|
6998404 |
Treatment or prevention of acute renal failure
Adenosine receptor antagonists, especially aminophyllline, are used to treat or prevent acute renal failure. In the preferred embodiment, aminophylline is administered by infusion so that it does...
|
|
|
6962921 |
Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
Medicines for treatment or prevention of dementia comprising 2-aryl-8-oxodihydropurine derivatives of the formula (I):
wherein W is H, C 1-6 alkyl, halogen, C 1-6 alkoxy, or the like; X is...
|
|
|
6936618 |
Cystic fibrosis medicaments
The use of a type V cyclic nucleotide phosphodiesterase inhibitor for the preparation of a medicament for the treatment of cystic fibrosis.
|
|
|
6894045 |
Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
Compounds provided herein are novel substituted tetrahydropurinones of Formula (I):
wherein R 3 is aryl substituted with 0-5 X Ar or heteroaryl substituted with 0-4 X hAr . Such compounds...
|
|
|
6790841 |
2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of...
|
|
|
6770645 |
Pharmaceutically active compounds
Compound of general formula I: wherein R 1 , R 2 , R 3 , R 4 , X, Y and R 5 have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for...
|
|
|
6747016 |
Substituted purine derivatives as inhibitors of cell adhesion
The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R 1 , R 2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their...
|
|
|
6734187 |
Purine derivatives and medicaments comprising the same as active ingredient
Purine derivatives represented by the following formula and salts thereof: wherein R 1 represents a C 1 -C 4 alkyl group or difluoromethyl group; R 2 represents tetrahydrofuranyl group, a C 1...
|
|
|
6730677 |
Benzofurazan compounds which enhance AMPA receptor activity
Compounds of general structural formula ( 1 ) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors...
|
|
|
6693105 |
Hydroxyl-containing compounds
Disclosed are therapeutic compounds having the formula: (R) j —(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer...
|
|
|
6630478 |
Methods for treatment of drug-induced peripheral neuropathy
A method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of...
|
|
|
6630490 |
Methods for treatment of disease-induced peripheral neuropathy and related conditions
A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine derivative or analogue,...
|
|
|
6548490 |
Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically...
|
|
|
6514980 |
Nucleoside analogs in combination therapy of herpes simplex infections
A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or penciclorivir/famciclovir, and an immunosuppressant, as a combined...
|
|
|
6486166 |
Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections
An important aspect of the present invention is a method for inhibiting proliferation of a DNA virus dependent upon events associated with cell proliferation for replication. The DNA virus includes...
|
|
|
6476037 |
L-arginine and phosphodiesterase (PDE) inhibitor synergism
This invention pertains to the discovery that L-arginine and type V phosphodiesterases act synergistically to inhibit vasospasm and/or to induce vasodilation. Methods are provided using...
|
|
|
6440981 |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.
|
|
|
6432967 |
Enema and enterically-coated oral dosage forms of azathioprine
This invention relates to enema and enterically-coated dosage forms having an amount of azathioprine effective to prevent colorectal adenomas without dose-limiting systemic toxicity.
|
|
|
6372740 |
2-aryl-8-oxodihydropurine derivative, process for the producing the same, medicinal compositions containing the same, and intermediates thereof
2-Aryl-8-oxodihydropurine derivative of the following formula (I): wherein W is H, lower alkyl, halogen, lower alkoxy, amino, mono- or di-lower alkylamino, or substituted or unsubstituted...
|
|
|
RE37650 |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline...
|
|
|
6333331 |
Substituted O6-benzylguanines
The present invention provides AGT inactivating compounds such as substituted O 6 -benzylguanines of the formula ##STR1## 7- or 9-substituted 8-aza-O 6 -benzylguanines, 7,8-disubstituted O 6 ...
|
|
|
6310070 |
Purine derivatives and medicinal use thereof
A novel purine derivative exhibiting an effect to control inflammatory symptoms characteristic to nephritis and a medicine comprising this compound as an effective ingredient are provided. The...
|
|
|
6288069 |
Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
The present invention comprises a method of stimulating regeneration or survival of a mammalian motor neuron or of a mammalian sensory neuron comprising administering to a mammal an effective...
|
|
|
6268373 |
Trisubstituted thioxanthines
Disclosed is a compound selected from the group consisting of 1,3,8-triethyl-2,6-dithioxanthine; 1,3,8-triethyl-2-thioxanthine; 8-cyclopropyl-1-ethyl-3-(2-methyl-butyl)-6-thioxanthine;...
|
|
|
6258809 |
6-aryloxy and arylthiopurines
Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by...
|
|
|
RE37234 |
Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
Disclosed are nitrosated and/or nitrosylated phosphodiesterase inhibitors having the formula NO n -PDE inhibitor where n is 1 or 2. The invention also provides compositions comprising such...
|
|
|
6110923 |
Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
The present invention covers a method of treatment of cancer, in particular, colon carcinoma, comprising the step of administering the compound N2-(6-dimethylamino...
|
|
|
6103729 |
Cathecol derivatives and a method for the preparation thereof and a pharmaceutical composition containing the same
A phosphodiesterase IV inhibiting cathecol derivatives of the general formula I: ##STR1## or a pharmaceutically acceptable salt thereof in which R1 is C 1 -7 alkyl; C 3 -7 cycloalkane; phenyl...
|
|
|
5958932 |
Substitutes O.sup.6 -benzylguanines, compositions, and methods of using same
The present invention provides AGT inactivating compounds such as substituted O 6 -benzylguanines of the formula ##STR1## wherein, for example, R 1 is amino, hydroxy, or alkylamino, R 2 is...
|
|
|
5912252 |
Purine and guanine derivatives as PNP inhibitors
The subject invention concerns compounds of formula (I): wherein n=1 or 2; R 1 is H, NH 2 or halogen; R 2 is H or NH 2 ; R 3 represents the group CR 6 R 7 R 8 where R 6 , R 7 ...
|
|
|
5905081 |
Topical formulations of azathioprine to treat inflammatory bowel disorders
A method is provided to treat inflammatory bowel disease by topically administering to the colon an effective amount of azathioprine or a pharmaceutically acceptable salt thereof, preferably via...
|
|
|
5866571 |
9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones
9-Substituted 2-(2-n-alkoxyphenyl)purin-6-ones are prepared by cyclizing correspondingly substituted imidazoles and derivatizing the purines thus obtained. The 9-substituted 2 ...
|
|
|
5863921 |
Purine and guanine derivatives
Compounds of formula (I) ##STR1## wherein n=1 or 2; R 1 is H, NH 2 or halogen; R 2 is H or NH 2 ; R 3 represents the group ##STR2## where m=0 or 1; R 4 and R 5 are the same or...
|
|
|
5861404 |
2,9-disubstituted purin-6-ones
2,9-Disubstituted purin-6-ones are prepared by acylating correspondingly substituted aminoimidazoles in a first step and then cyclizing the product to the purine. The new 2,9-disubstituted...
|
|
|
5773424 |
Treatment of toxoplasmosis
Pharmaceutical compositions comprising a pharmaceutical composition comprising a compound which is an α or β anomer, a D(+) or L(-) enantiomer of the following structural formula: ##STR1##...
|
|
|
5736549 |
Hypoxanthine and guanine compounds
Compounds of formula I ##STR1## where n=0-2; R 1 is H, NH 2 or a halogen; R 2 is H or NH 2 ; R 3 is any of the four groups ##STR2## where m=0 or 1; and X is O, NR 5 , or S(O) 0 -2...
|
|
|
5733915 |
Use of azathioprine to treat crohn's disease
A therapeutic method for the treatment of Crohn's disease is provided, comprising administering to a patient in need of said treatment an intravenous dose of azathioprine or a pharmaceutically...
|
|
|
5733916 |
Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
Methods of preventing or treating ischemia-reperfusion injury in an organ by administration of a composition containing a selective A 1 adenosine receptor antagonist and/or a P 2X purinoceptor...
|